Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease

Varespladib methyl in cardiovascular disease

(2010) Robert S Rosenson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients

(2010) Robert S. Rosenson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A-002 (Varespladib), a phospholipase A2inhibitor, reduces atherosclerosis in guinea pigs

(2009) Jose O Leite et al.   BMC Cardiovascular Disorders

Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease

(2009) Robert S. Rosenson   CARDIOVASCULAR DRUGS AND THERAPY

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

(2009) Robert S Rosenson et al.   LANCET

Biochemistry and Physiology of Mammalian Secreted Phospholipases A2

(2008) Gérard Lambeau et al.   Annual Review of Biochemistry

The synergistic inhibition of atherogenesis in apoE−/−mice between pravastatin and the sPLA2inhibitor varespladib (A-002)

(2008) Zory Shaposhnik et al.   JOURNAL OF LIPID RESEARCH

Highly Specific and Broadly Potent Inhibitors of Mammalian Secreted Phospholipases A2

(2008) Rob C. Oslund et al.   JOURNAL OF MEDICINAL CHEMISTRY